Adocia inks insulin lispro and insulin glargine supply deal with Chinese firm

French biotech Adocia (Euronext Paris: ADOC) and Tonghua Dongbao Pharmaceuticals (SSE: 600867) announced today an expansion of their strategic alliance with the latter to manufacture and supply insulin lispro and insulin glargine APIs to Adocia worldwide, excluding China, with the news raising the French firm’s shares by more than 3% to 19.80 euros by close of trading.

“We are very pleased to strengthen our strategic alliance with Tonghua Dongbao and enter global supply agreements for insulin lispro and insulin glargine. These agreements give us full control, outside China, over the further development of BioChaperone Lispro, our ultra-rapid insulin, and BioChaperone Combo, our combination of insulins glargine and lispro,”said Gérard Soula, chief executive of Adocia, adding:“This also opens additional collaboration opportunities with biopharmaceutical companies focused in diabetes with no existing insulin manufacturing facilities and, also, device companies integrating synergies between innovative medicines, devices and care management systems.”

Has several state-of-the-art manufacturing facilities